October 04, 2026 06:11 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Asian Games 2026: India beat Pakistan to clinch gold in men's cricket | flydubai cockpit attack: Deleted posts expose Omani co-pilot’s views on women, alleged extremist past | flydubai cockpit horror: Omani co-pilot Hamam al-Hammami attacked Captain Smit Machchhar with crash axe, tried to seize control | flydubai temporarily suspends all Israel flights after co-pilot’s alleged cockpit attack, crash attempt | Grounded in Oman over ‘radical views’, then hired by flydubai: What we know about Omani pilot Hamam al-Hammami | ‘Hanuman Chalisa gave me courage’: Smit Machchhar recounts flydubai cockpit battle to PM Modi | PM Modi speaks to Flydubai pilot Smit Machchhar who foiled crash plot, praises his courage | Putin praises Modi’s ‘good ideas’ to end Ukraine war, thanks Indian PM for peace efforts | Flydubai cockpit attack: Injured Indian pilot Smit Machchhar airlifted to Abu Dhabi | India backs brave flydubai pilot Smit Machchhar, Ambassador meets family after cockpit attack
Japan I Covid19
Image Cr: Unsplash

Japan approves home-made Covid-19 cure for emergency use

| @indiablooms | Nov 24, 2022, at 06:44 pm

Tokyo/UNI: The Japanese Health Ministry has authorised the island nation's first locally made COVID-19 oral treatment, Xocova, for emergency use.

This emergency approval was granted on the anticipated efficacy of Xocova and the acceptability of its safety profile based on the results obtained through the Phase 2 part (497 cases including the Phase 2a and Phase 2b parts combined) and the Phase 3 part (1,821 cases) of the Phase 2/3 study.

The pill was developed by Osaka-based pharmaceutical firm Shionogi & Co to treat coronavirus patients after they develop initial symptoms, such as fever, cough, a sore throat, a runny nose, and fatigue.

Xocova is an oral antiviral agent administered once daily for five days that suppresses the replication of SARS-CoV-2 by selectively inhibiting the viral 3CL protease.

It has been proven the most effective when administered during the first three days of symptoms starting.

The drug is known to reduce the viral load to three percent when taken on day four, and is not recommended for use during pregnancy.

Shionogi had filed for manufacturing and sales approval on Feb. 25, 2020.

The company said it had enough pills to treat one million people, and the drug will hit the shelves in Dec.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.